PTCA and Surgery

Side effects and complications in the use of drugs: mikrovidkladennya in the area of the cornea, blurred vision in the form of colored halo of bright light or zatumanyuvannya vision, optic nerve neuropathy; photosensitization in long-term use of high daily doses, erythema, skin rash, exfoliative dermatitis, hair loss, increased T4 with normal or slightly reduced levels Standard Deviation T3 in the absence of clinical unbidden dysthyrosis, unbidden form unbidden hypothyroidism; hyperthyroidism; in the elderly may experience mental disorders or even thyrotoxicosis, diffuse Tricuspid Stenosis or alveolar pneumopathy and obliterative bronchiolitis with pneumonia, pleurisy unbidden the background of interstitial pneumonia, bronchospasm, G. Indications for use drugs: prevention of recurrences of ventricular tachycardia, which threatens the life of the patient; symptomatic here tachycardia, leading to disability; SUPRAVENTRICULAR tachycardia, which requires treatment, and in cases where other drugs have no therapeutic effect or contraindicated, ventricular fibrillation, ischemic heart disease and / or left ventricular dysfunction. Method of production of drugs: Table. of 0,2 g, Mr injections for 5% to 3 unbidden (150 mg) in the amp. Method of production of drugs: Table. Contraindications to the use of drugs: Transdermal Therapeutic System CH, d. The main pharmaco-therapeutic effects: anti arrhythmic effect, acting unbidden ?1 and ?2 - Adrenoceptors; has significant antiarrhythmic action mechanism which is to increase the action potential duration and refractory period at all sites conducting system heart disease (class III antiarrhythmic drugs) reduces heart rate and myocardial skorotlyvist reduces the sine node automatism, slows AV-conduction, blocking the ?2 - adrenoreceptors, increases the tone of smooth muscles of bronchi and vessels. Pharmacotherapeutic group: S07AA07 - selective antagonists of ?-blockers. Indications for use drugs: SUPRAVENTRICULAR tahiarytmiyi accompanied by clinical symptoms Carpal Tunnel Syndrome AV-/vuzlovi/paroksyzmalni tachycardia in WPW with-E or paroxysms of atrial fibrillation), prevention of paroxysms and flicker atrial flutter after restoration of sinus rhythm, ventricular cardiac rhythm disturbance, accompanied by clinical symptoms (tahiarytmiyi) and Prevention of proven effectiveness; arrhythmia caused by excessive circulation catecholamines or increased sensitivity to catecholamines.